Homepage Archives - Geneseeq Technology Inc. | A Precision Oncology Company

August 22, 2023

Geneseeq Gains CE Marks for NGS-based Test Kits for Solid Tumors and Hematological Cancer

May 25, 2023

GENESEEQ TO SHOWCASE NEW FINDINGS AT ASCO 2023

May 16, 2023

Geneseeq published new research on the clinical use of circulating-free DNA fragmentomic in monitoring minimal residual disease for patients with non-small-cell lung cancer

April 13, 2023

Geneseeq co-publish with UHN on using ctDNA as a prognostic biomarker for immunotherapy

March 9, 2023

Geneseeq and Collaborators Initiate MOTION Study to Evaluate the Performance of Minimal Residual Disease Test SHIELDING™ in Early-stage Lung Cancer

January 24, 2023

Geneseeq receives CE Marks for MRD and MCED tests.

November 3, 2022

Geneseeq study evaluates the clinical value of cell-free DNA 5’-end motif profile in the prediction of pathological complete response for LARC patients after neoadjuvant chemoradiotherapy

October 18, 2022

Geneseeq study highlights ctDNA monitoring clinical value in colorectal cancer patients resistant to BRAF/EGFR-targeted therapy

October 12, 2022

Interesting findings on ctDNA-based MRD detection in patients with resectable non-small cell lung cancer by Geneseeq

September 7, 2022

Geneseeq to present five posters at European Society for Medical Oncology 2022